GLP-1 and Bone Health: The Osteoporosis Risk Nobody Expected

A 29% increase in osteoporosis risk: the number that got everyone's attention

At the March 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans, a research team led by Muaaz Wajahath at Michigan State University presented data that shifted the conversation around GLP-1 medications. After analyzing 73,483 matched patients from a multi-institutional electronic medical records database, they found that GLP-1 receptor agonist users had a 29% higher risk of developing osteoporosis over five years compared to matched controls who weren't taking the drugs.

The raw numbers: 4.1% of GLP-1 users developed osteoporosis versus 3.2% of nonusers (risk ratio 1.29, p<0.001). That gap may sound modest in absolute terms, but given that tens of millions of people now take these medications, even a small percentage-point difference translates to a large number of affected individuals.

The findings didn't stop at osteoporosis. Osteomalacia, a condition where bones soften and become prone to bending and fracturing, showed the steepest relative increase: a risk ratio of 2.55, meaning GLP-1 users were more than twice as likely to develop the condition (2% versus 0.1% in controls). Gout risk also climbed by 12%, with 7.4% of GLP-1 users affected compared to 6.6% of nonusers.

The AAOS study matched patients on age, sex, race, BMI, hemoglobin A1c, tobacco use, and comorbid conditions including chronic kidney disease and rheumatoid arthritis. This is a retrospective observational study that has not yet been peer-reviewed.

This wasn't the only warning sign that emerged around the same time. A separate study published in the Journal of Clinical Endocrinology and Metabolism tracked 46,177 older adults with type 2 diabetes using Israel's Clalit Health Services database. Over a median follow-up of nearly three years, GLP-1 receptor agonist users had an 11% higher risk of fragility fractures compared to people taking other diabetes medications (hazard ratio 1.11, 95% CI 1.01-1.21).

Dr. John Horneff, an orthopedic surgery professor at the University of Pennsylvania, told NBC News he began investigating after noticing some patients developing serious tendon tears from relatively minor injuries. That clinical observation led his team to look at bone health more broadly. The practical takeaway from the AAOS data: if you're on a GLP-1 medication, bone health should be part of the conversation with your doctor, not an afterthought.

Why Mounjaro's bone signal stands out from the pack

Not all GLP-1 medications appear equal when it comes to bone risk. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, targets two receptors instead of one. While semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor, tirzepatide is a dual GLP-1/GIP receptor agonist, hitting both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) pathways simultaneously.

That dual mechanism drives more aggressive weight loss, but it may also carry steeper skeletal consequences. A retrospective cohort study from Taiwan's National Cheng Kung University, using the TriNetX database of 459,886 patients with type 2 diabetes or obesity, found that tirzepatide users had a 44% higher risk of osteoporosis or fragility fractures compared to users of other GLP-1 receptor agonists (hazard ratio 1.44, 95% CI 1.22-1.69). After propensity score matching balanced the two groups at 66,329 participants each, the gap held firm.

The comparison to non-medication users was even more telling. Tirzepatide users faced a 48% higher risk compared to nonusers (HR 1.48, 95% CI 1.26-1.75), while other GLP-1 receptor agonists showed only a borderline 7% increase (HR 1.07, 95% CI 1.00-1.15) that barely reached statistical significance. Tirzepatide users were also 61% more likely to start osteoporosis treatment during the follow-up period (HR 1.61, 95% CI 1.22-2.12).

Why the difference? Two factors likely converge. First, tirzepatide produces more weight loss than semaglutide, and greater weight loss correlates more strongly with bone density decline. Second, bone is metabolically active tissue that responds to incretin hormones like GLP-1 and GIP. Activating both receptors at once may alter bone remodeling in ways we don't yet fully understand. Think of it like turning two dials at once instead of one: the combined effect on the skeletal system may not simply be additive.

This doesn't mean everyone on tirzepatide will develop bone problems. The absolute risk remains relatively low. But the signal is strong enough that bone health monitoring deserves extra attention for tirzepatide users, particularly those who already carry risk factors like older age, female sex, or low baseline bone density.

The plot twist: diabetes patients may actually see bone protection

The same class of drugs that appears to weaken bones in some populations may strengthen them in others. The dividing line is whether or not you have diabetes.

A February 2026 study published in the Journal of Clinical Endocrinology and Metabolism by Liu et al. at Weill Cornell Medical College tracked 255 patients on semaglutide or tirzepatide matched against 255 controls. The results split cleanly by diabetes status. Among patients without diabetes, GLP-1 receptor agonist users lost 1% of total hip bone mineral density per year, while their matched controls actually gained 0.6% (P=.04). Among patients with diabetes, there was no meaningful difference between the groups.

The most surprising finding involved patients with both diabetes and severe obesity (class II or greater). In that subgroup, GLP-1 receptor agonist users showed a tiny BMD gain of +0.1%, while controls lost 1.0%. The difference didn't reach statistical significance in this smaller subgroup (P=.20), but the direction was opposite to what the headline findings might suggest.

Larger studies reinforce this pattern. A Chinese real-world cohort of 1,845 type 2 diabetes patients published in Frontiers in Endocrinology found that GLP-1 receptor agonist users had a 31% lower risk of developing osteoporosis (hazard ratio 0.69, 95% CI 0.45-0.84). That protective effect held across subgroups divided by age, sex, BMI, and smoking status.

The largest study to date paints a similar picture. A nationwide Danish study published in Osteoporosis International in March 2026 compared 337,648 people who sustained fractures against 675,296 matched controls without fractures. After adjusting for relevant risk factors, GLP-1 receptor agonist users were 6% less likely to have experienced any fracture (odds ratio 0.94, 95% CI 0.90-0.97) and 12% less likely to have had a major osteoporotic fracture (OR 0.88, 95% CI 0.83-0.94).

How do we reconcile these contradictory findings? Dr. Susan Spratt, an endocrinologist at Duke Health, raised the central question: is the increased risk coming from the rapid weight loss itself, or from some direct mechanism of the drug? The emerging answer appears to be "mostly the weight loss." In diabetes patients, where the metabolic benefits of GLP-1 medications (better blood sugar control, reduced inflammation) may offset the skeletal costs of weight loss, the net effect on bone seems neutral or positive. In non-diabetic obesity patients taking these drugs purely for weight management, the bone costs of rapid weight loss may go unchecked by those metabolic benefits.

So the practical question for any GLP-1 user: does your specific combination of health status, weight loss rate, and protective habits (exercise, nutrition, monitoring) add up to net benefit or net harm for your skeleton? The answer depends on factors within your control.

Your bones were built for the body you had

Dr. Clifford Rosen, a professor of medicine at Tufts University who studies GLP-1 bone effects, put it bluntly: "Weight loss does cause bone loss." The question his team is investigating is whether that loss represents normal skeletal adaptation or something more dangerous.

Dr. John Horneff offered an analogy that sticks. He compared GLP-1-driven bone loss to what happens to astronauts in zero gravity: "There's nothing forcing their bones to kind of hold their weight anymore. And a lot of those astronauts come back with low bone density." Your skeleton builds itself to support the load it carries every day. When that load drops by 15-20% of your body weight over months, the skeleton starts dismantling infrastructure it no longer thinks it needs.

A comprehensive review published in Nature's Bone Research identifies five interconnected mechanisms through which weight loss damages bone:

Mechanism	What happens	Why it matters for GLP-1 users
Reduced mechanical loading	Less body weight means less physical force on bones during daily activity	GLP-1 drugs produce 15-20% weight loss, far exceeding the 5-10% from older medications
Bone marrow adiposity	Fat cells infiltrate bone marrow and crowd out bone-forming osteoblasts	Rapid fat loss may paradoxically increase marrow fat before the body recalibrates
Hormonal disruption	Drops in IGF-1, estrogen, and parathyroid hormone destabilize bone remodeling	Caloric restriction from appetite suppression amplifies hormonal shifts
Nutritional deficiency	Reduced food intake means less calcium, vitamin D, and protein reaching bones	GLP-1 appetite suppression makes eating enough nutrients genuinely difficult
Energy metabolism changes	The body in caloric deficit diverts energy away from bone maintenance	Sustained caloric deficit is the primary mechanism through which GLP-1 drugs work

The speed of weight loss compounds these effects. Research cited in Osteoporosis International shows that intensive weight loss of 7% or more in adults around age 60 produces hip bone density decreases that persist for at least three years, even after weight stabilizes. GLP-1 medications routinely produce 15-20% weight loss, meaning the skeletal challenge is significantly larger than what older weight-loss approaches created.

A randomized clinical trial from the University of Copenhagen, published in JAMA Network Open, quantified this directly. Among 195 adults with obesity, those taking liraglutide (a GLP-1 receptor agonist) alone experienced measurable reductions in bone mineral density at the hip (P=.03) and spine (P=.04) compared to an exercise-only group, despite similar total weight loss between the two groups. The weight came off at similar rates, but the liraglutide group's bones suffered more. A 52-week trial reviewed in Nature's Bone Research found that semaglutide increased CTX, a marker of bone breakdown, in adults already at high fracture risk.

The correlation between weight loss magnitude and bone loss is direct and measurable. In the Weill Cornell study, weight reduction correlated with total hip bone loss at r=0.32 and femoral neck bone loss at r=0.17 (both P<.01). Lose more weight, lose more bone. That makes the case for proactive bone protection pretty straightforward.

The exercise prescription that actually preserved bone density

The same Copenhagen trial that showed GLP-1 drugs alone can damage bone density also produced the most encouraging data available. The group that combined liraglutide with a structured exercise program lost the most weight of any group, an average of 16.88 kilograms, yet their bone mineral density at the hip and spine remained statistically indistinguishable from placebo. They lost more weight and kept their bones.

Compare that to liraglutide alone (13.74 kg weight loss with measurable BMD decline) or exercise alone (11.19 kg with preserved BMD). The combination group got the outcome everyone wants: maximum weight loss without sacrificing bone. As Dr. Christopher McGowan, a gastroenterologist running a weight-loss clinic in North Carolina, told NBC News, "when GLP-1s are combined with structured exercise, bone density loss is largely mitigated."

What did the exercise look like? Four sessions per week: two supervised group sessions consisting of 30 minutes of vigorous interval cycling followed by 15 minutes of circuit training (3 circuits of 5 exercises at 40-second intervals), plus two individual sessions of participants' choosing at moderate-to-vigorous intensity. The target heart rate during group sessions was 80% of maximum.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases recommends three categories of exercise for bone health, and GLP-1 users should hit all three:

Exercise type	How it helps bones	Examples
Weight-bearing	Produces force on bones that stimulates density maintenance	Brisk walking, jogging, dancing, stair climbing, racket sports
Resistance training	Puts direct stress on bones through muscle-tendon attachment points	Free weights, machines, resistance bands, bodyweight exercises
Balance training	Prevents falls that lead to fractures, especially in older adults	Tai chi, single-leg stands, step-ups, walking backward

The NIH minimum for adults: 150 minutes per week of moderate-intensity activity or 75 minutes of vigorous activity, plus muscle-strengthening exercises at least twice weekly. For GLP-1 users concerned about bone health, that minimum should be treated as a floor, not a target. The Copenhagen trial used vigorous exercise four times per week, which goes beyond the baseline NIH recommendation. If you're also concerned about preventing muscle loss on GLP-1 medications, resistance training does double duty: it loads your bones and protects your lean mass simultaneously.

Nutrition is the other half. GLP-1 drugs suppress appetite, which means you eat less. Eating less means fewer nutrients reaching your bones unless you're deliberate about it. The NIH recommends adults under 50 get 1,000 mg of calcium daily, rising to 1,200 mg for women over 50 and men over 70. Vitamin D intake should be at least 600 IU per day for adults up to age 70 and 800 IU for those older. UC Davis Health experts also recommend ensuring adequate magnesium and emphasize high-quality protein with every meal.

When your appetite is suppressed, every calorie has to work harder. Prioritize calcium-rich foods (dairy, sardines, leafy greens), vitamin D sources (fatty fish, fortified milk), and complete protein. A multivitamin may help fill gaps but shouldn't replace food sources. For detailed muscle-sparing nutrition protocols while on GLP-1 medications, see our companion guide.

Bone density tests, blood work, and the conversations to have now

The US Preventive Services Task Force recommends routine DXA bone density screening for all women aged 65 and older and for postmenopausal women under 65 who have risk factors for osteoporosis. For men, the evidence is currently insufficient for a blanket recommendation, though clinicians are encouraged to use judgment.

GLP-1 medication use doesn't yet appear on any standard screening guideline as an independent risk factor for early DXA scanning. But the accumulating evidence suggests it should be considered. The FDA's prescribing information for semaglutide already notes a possible increased fracture risk in older adults and women, according to Dr. Clifford Rosen of Tufts University.

Given the research findings, GLP-1 users — particularly those without diabetes, those on tirzepatide, postmenopausal women, and adults over 60 — should discuss baseline bone density testing with their doctors before or shortly after starting medication. A DXA scan before you begin provides a reference point. Follow-up scans can then track whether your bone density is changing.

Risk factor	Why it matters for GLP-1 users	Action
Female sex, especially postmenopausal	27.1% of women 65+ already have osteoporosis	Baseline DXA before starting GLP-1; repeat per physician guidance
Age over 60	Bone loss from weight loss persists 3+ years in older adults	Discuss early DXA screening with your doctor
No diabetes diagnosis (using for weight loss only)	Non-diabetic users show greater bone loss than diabetic users	Extra vigilance on exercise and nutrition protocols
Using tirzepatide (Mounjaro/Zepbound)	44% higher bone risk than other GLP-1 RAs in large cohort study	Consider more frequent monitoring
Rapid weight loss (>7% body weight)	Greater weight loss correlates directly with greater bone loss	Ensure resistance training is part of your protocol

Wajahath, the lead AAOS investigator, put the monitoring recommendation directly: "Whenever you have a patient who is prone to osteoporosis, gout or osteomalacia, clinicians should consider bone health surveillance and monitor for delayed-onset complications in at-risk populations." He added that "these changes can be implemented immediately and can be an easy fix to potentially prevent these side effects."

This matters beyond abstract risk percentages. According to the USPSTF, only 40-60% of people who experience a hip fracture recover their previous level of mobility and ability to perform daily activities. Fractures from osteoporosis aren't just painful inconveniences. They change lives permanently, and they're largely preventable with early detection and intervention.

McGowan framed the overall message well: "The takeaway isn't fear. It's refinement." GLP-1 medications work. The bone data doesn't argue against using them. It argues for paying attention to what else your body needs while the weight comes off.

Frequently Asked Questions

Do GLP-1 medications directly damage bones, or is it the weight loss?

The evidence increasingly points to weight loss as the primary driver. A 2026 study from Weill Cornell showed that non-diabetic GLP-1 users lost significantly more bone density than controls, while diabetic users showed no difference. The weight loss correlation was direct and measurable. However, a 52-week trial cited in Bone Research found semaglutide increased a bone resorption marker, so a direct drug effect hasn't been ruled out entirely. Researchers are still investigating whether GLP-1 medications alter bone remodeling independent of weight loss.

Should I get a bone density scan before starting Ozempic or Wegovy?

If you're a postmenopausal woman, over 60, or have other risk factors for osteoporosis (family history, low body weight, smoking, steroid use), a baseline DXA scan before starting GLP-1 treatment is a reasonable conversation to have with your doctor. The USPSTF already recommends DXA for women 65+ and younger postmenopausal women with risk factors. GLP-1 use adds another reason to consider early screening.

Is tirzepatide (Mounjaro/Zepbound) worse for bones than semaglutide?

A large retrospective study of nearly 460,000 patients found tirzepatide users had a 44% higher risk of osteoporosis or fractures compared to users of other GLP-1 receptor agonists. This may relate to tirzepatide's greater weight loss effect and its dual receptor mechanism. However, this was a single retrospective study, and no head-to-head randomized trial has directly compared their bone effects yet.

Can exercise really prevent bone loss while I'm on GLP-1 medications?

The strongest evidence says yes. In a randomized clinical trial from Copenhagen, participants who combined a GLP-1 drug with vigorous exercise four times weekly lost the most weight (16.88 kg average) while preserving bone density at the hip and spine. The exercise group that didn't take the medication also preserved bone density with less weight loss. Resistance training and weight-bearing exercise are the most effective types for bone protection.

How much calcium and vitamin D should GLP-1 users take?

The NIH recommends 1,000 mg of calcium daily for adults under 50 (1,200 mg for women over 50 and men over 70) and 600 IU of vitamin D for adults up to 70 (800 IU over 70). Because GLP-1 medications suppress appetite and reduce food intake, meeting these targets through diet alone becomes harder. Discuss supplementation with your doctor, and prioritize calcium-rich foods at every meal.